$CMMB News

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

CORRECTION: Chemomab Therapeutics Q2 EPADS $(0.27) Misses $(0.15) Estimate

Chemomab Therapeutics Ltd. (CMMB) Chemomab Therapeutics Ltd., - M&A Call - Slideshow

Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

Chemomab Therapeutics, Scipher Medicine Strike All-Stock Merger Agreement; Combined Entity Expected To Operate Under Scipher Medicine Name, SCIP Ticker On Nasdaq

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics Q1 EPS $(0.24) Beats $(0.31) Estimate

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Chemomab Therapeutics Q4 EPS $(0.24) Beats $(0.40) Estimate

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Chemomab Therapeutics Data From Phase 2 SPRING Study Shows Nebokitug Was Safe, Well Tolerated In Participants With Primary Sclerosing Cholangitis At Up To 48 Weeks Of Treatment

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Therapeutics Q3 EPS $(0.28) Beats $(0.40) Estimate

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

Chemomab To Present Abstracts Highlighting New Clinical Data From Nebokitug Phase 2 SPRING Trial In Primary Sclerosing Cholangitis, At AASLD 2025

Oppenheimer Maintains Outperform on Chemomab Therapeutics, Raises Price Target to $25

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending